4 Healthcare Stock Stories Prescribed For Savvy Investors

GlaxoSmithKline (NYSE: GSK): Closing price $52.42

GlaxoSmithKline reported Thursday that the FDA has okayed both Taflinlar (dabrafenib) and Meknist (trametinib). Tafinlar is indicated as a single-agent oral treatment for unresectable melanoma or metastatic melanoma in adult patients with BRAF V600E mutation. Tafinlar is not indicated for the treatment of patients with wild-type BRAF melanoma. Mekinist is indicated as a single-agent oral treatment for unresectable or metastatic melanoma in adult patients with BRAF V600E or V600K mutations, but is not indicated for the treatment of patients who have received a prior BRAF inhibitor therapy. These mutations must be detected by an FDA-approved test, like the companion diagnostic assay from bioMerieux S.A., THxID-BRAF.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GSK

Biogen IDEC (NASDAQ:BIIB): Closing price $238.89

Biogen anticipates a delay in the European debut of its multiple sclerosis drug Tecfidera, as the company works to obtain exclusive data that could potentially protect its treatment from generic rivals for a longer period. In a filing, the company said that it was endeavoring ensure that the drug’s regulatory data protection cleares prior to the launch, and expects the European introduction to be delayed until the second half of this year.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BIIB

Teva Pharmaceutical Industries (NYSE: TEVA): Closing price $38.83

On Thursday, Teva announced that it will pay $91 million in taxes under Amendment 69 to the Law for the Encouragement of Capital Investments, and is considering the idea of paying an additional amount by November. The law presently permits Israeli firms to use tax-exempt profits accumulated before the end of 2011 for dividends, so long as certain reduced taxes are paid.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

TEVA

 Idenix Pharmaceuticals (NASDAQ:IDIX): Closing price $4.55

Idenix reported the start of the phase II HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral HCV combination regimen of samatasvir (IDX719), Idenix’s once-daily pan-genotypic NS5A inhibitor, and simeprevir (TMC435), a once-daily protease inhibitor jointly created by Janssen R&D Ireland and Medivir AB. Idenix is a biopharmaceutical firm engaged in the discovery and development of drugs for the treatment of human viral diseases.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

IDIX

Don’t Miss: Do Americans Desperately Need a Paid Vacation?